LogicBio Therapeutics Appoints Dean Falb, Ph.D., as Chief Scientific Officer
Genome editing company adds drug development expert in pursuit of breakthrough medicines for pediatric patients
Cambridge, Mass., May 23, 2018 – LogicBio Therapeutics, Inc., a genetic medicine company founded to develop safe and lasting treatments for children with life-threatening early onset diseases, today announced the appointment of Dean Falb, Ph.D., as chief scientific officer. Dr. Falb, who most recently served as chief technology officer at Synlogic Therapeutics, brings more than 20 years of drug discovery and development experience to the LogicBio leadership team.
“Dean is a recognized leader with extensive experience building strong research and development teams, and his background as a scientist and entrepreneur further enables our strategic mission to develop genome editing therapeutics for children struggling with genetic disease,” said LogicBio Chief Executive Officer Fred Chereau. “His insight in essential areas such as planning and executing research strategy, and the development and expansion of platform technologies, will be a critical component in the next stage of our corporate evolution.”
As chief technology officer and co-founder of Synlogic, Falb led the company’s effort to develop engineered synthetic microbes for rare disease and oncology applications. Prior to Synlogic, he was an entrepreneur in residence at Atlas Ventures, where he helped guide the launch of several early stage life sciences companies. From 2005 to 2012, he served as vice president of research at Stryker Regenerative Medicine. In this role, Dr. Falb led the discovery and development of a portfolio of bone morphogenic protein drugs in osteoarthritis. He has also held leadership positions at Praecis Pharmaceuticals, Inc., NeoGenesis Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. He received his doctoral degree in biochemistry and molecular biology from Harvard University. As chief scientific officer, Dr. Falb will guide research strategy and drive innovation as LogicBio advances multiple product development programs into the clinic.
“LogicBio is uniquely committed and positioned to deliver a new future for pediatric patients with genetic disease,” said Falb. “I look forward to working with this talented team to pursue this transformational opportunity and realize the promise and potential of the company’s innovative GeneRide™ technology.”
About LogicBio Therapeutics
LogicBio Therapeutics is a genetic medicine company, founded to deliver the benefits of genome editing to the fight against early onset childhood diseases. Launched in 2016 by pioneers in gene therapy from Stanford University and funded by leading life science investors, LogicBio is developing a pipeline of safe and durable treatments for pediatric indications. Our core technology, GeneRide™, enables the site-specific integration of a therapeutic transgene, in a nuclease-free and promotorless approach by relying on the native process of homologous recombination to drive lifelong expression. With a world-class global team headquartered in Cambridge, Massachusetts, LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.
For more information, please visit www.logicbio.com.
Media: Paul Goldsmith, Ten Bridge Communications